ATAI Chairman Predicts his Company will Capture most of a Market Generating over 40b in Revenue a Year. https://x.com/c_angermayer/status/1948412665065332773?s=46&t=vUrFTxjVRaTfEod7uaEXDA History shows how hard it is to grasp paradigm shifts early, especially in biotech/pharma: A decade ago, most analysts predicted cancer immunotherapy would peak at ~$5-10B annual revenues. Today, the top three checkpoint inhibitors generate $41B+ annually. I expect the same if not bigger smashing success for psychedelics. Because in mental health, unfortunately, the addressable population is even larger: ~17 million Americans have cancer. But nearly 80 million suffer from depression, anxiety, trauma, or substance use disorders. And countless more suffer in silence. And this number is only growing in our increasingly stress-inducing world. I believe $ATAI will capture most of those revenues, due to a mix of commercial reasons ("2-hour-window"), patents, formulations, delivery methods & more.
